Latest News and Press Releases
Want to stay updated on the latest news?
-
BUFFALO, N.Y., Sept. 12, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and...
-
SACRAMENTO, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Biotech company 22nd Century Group, Inc. (NASDAQ: XXII) this week launched VLN® King cigarettes, the first-ever reduced nicotine combustible...
-
BUFFALO, N.Y., July 12, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and...
-
HTL Is Commonly Used in Heat-Not-Burn and Cigar Binder and Wrapper Applications Provides VLN® Tobacco Solution in Large Adjacent Markets BUFFALO, N.Y., June 23, 2023 (GLOBE NEWSWIRE) -- 22nd...
-
Terrible Herbst and Speedee Mart Selling VLN® Reduced Nicotine Products in Approximately 200 Las Vegas Area Stores FDA Authorized VLN® Products Are Specifically Designed to Reduce the Harms of...
-
BUFFALO, N.Y., June 20, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis...
-
Accelerates VLN® Launch with Key National Distribution AgreementsLaunching VLN® in Texas, California and Florida with New National Scale Distributor and Retail PartnersScaling Hemp/Cannabis Revenue...
-
Accelerating VLN® Sales in Colorado and Illinois, Launching in Four Corners States to Capture Market Share and VolumeGVB Biopharma Acquisition Growing Revenue on Increased VolumesThird Quarter Net...
-
Combined with Ongoing Launch in Colorado, VLN® Will Be Available in All “Four Corners” StatesUtah and New Mexico Join Colorado as VLN® States with Favorable MRTP Excise Tax Programs BUFFALO, N.Y.,...
-
VLN® cigarettes from 22nd Century Group contain 95% less nicotine than conventional cigarettes, greatly reducing nicotine consumption to help smokers smoke less; support State and FDA goals of...